ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE and OSTEOPOROSIS

3 reports of this reaction

1.8% of all ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE reports

#15 most reported adverse reaction

Overview

OSTEOPOROSIS is the #15 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE, manufactured by Rite Aid Corporation. There are 3 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE to OSTEOPOROSIS. This represents approximately 1.8% of all 171 adverse event reports for this drug.

Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE who experience osteoporosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

OSTEOPOROSIS3 of 171 reports

OSTEOPOROSIS is a less commonly reported adverse event for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.

Other Side Effects of ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE

In addition to osteoporosis, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE:

Other Drugs Associated with OSTEOPOROSIS

The following drugs have also been linked to osteoporosis in FDA adverse event reports:

ATAZANAVIRBICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATEBISMUTH SUBSALICYLATEBUFFERED ASPIRINCALCIUM CARBONATE, MAGNESIUM HYDROXIDEDARUNAVIRDOLUTEGRAVIR SODIUMELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDEELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATEEMTRICITABINE AND TENOFOVIR ALAFENAMIDEEMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATELAMIVUDINE AND ZIDOVUDINELOPINAVIR AND RITONAVIRRALTEGRAVIRRILPIVIRINE HYDROCHLORIDERITONAVIRTENOFOVIR DISOPROXIL FUMARATETENOFOVIR DISOPROXIL FUMARATE TABLETS

Frequently Asked Questions

Does ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE cause OSTEOPOROSIS?

OSTEOPOROSIS has been reported as an adverse event in 3 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is OSTEOPOROSIS with ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE?

OSTEOPOROSIS accounts for approximately 1.8% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE, making it a notable side effect.

What should I do if I experience OSTEOPOROSIS while taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE?

If you experience osteoporosis while taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages

ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE Full ProfileAll Drugs Causing OSTEOPOROSISRite Aid Corporation Drugs
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.